SAN JOSE, Calif.,
March 11,
2024 /PRNewswire/ -- Anixa Biosciences,
Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a
clinical-stage biotechnology company focused on the treatment and
prevention of cancer, today announced that Dr. Amit Kumar, Chairman and CEO of Anixa, will
participate in the 24th Annual World Vaccine Congress
being held April 1-4, 2024. Dr. Kumar
will speak on Thursday, April
4th, in the Cancer Immunotherapy Track.
Details are as follows:
Location:
|
Walter E.
Washington Convention Center, Washington, D.C.
|
Tickets:
|
Visit
the conference website.
|
Session:
|
April 4, 2024 |
Cancer Immunotherapy
|
|
Emerging Targets &
Strategies track
|
|
11:45 a.m.:
"Early-stage clinical results from a novel preventative breast
cancer vaccine."
|
Dr. Kumar will speak about positive interim results from the
Phase 1 clinical trial of Anixa's breast cancer vaccine. In
the most recent data, 75% of women showed immune responses, with
responses observed at all dose levels. The vaccine is designed to
direct the immune system to destroy triple negative breast cancer
(TNBC) cancer cells through a mechanism that has never previously
been utilized for cancer vaccine development. The trial is being
conducted in collaboration with Cleveland Clinic with funding by a
grant from the U.S. Department of Defense.
Dr. Kumar will be available during the Congress for one-on-one
meetings.
The World Vaccine Congress is an award-winning series of
conferences and exhibitions that have grown to become the largest
and most established vaccine meetings of their kind across the
globe since 2000. The World Vaccine Congress Washington 2024 will
host 4,000+ attendees, 450+ speakers, and 350+ exhibitors.
About
Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the
treatment and prevention of cancer. Anixa's therapeutic portfolio
consists of an ovarian cancer immunotherapy program being developed
in collaboration with Moffitt Cancer Center, which uses a novel
type of CAR- T, known as chimeric endocrine receptor T-cell (CER-T)
technology. The Company's vaccine portfolio includes a novel
vaccine being developed in collaboration with Cleveland Clinic to
prevent breast cancer – specifically triple
negative breast cancer
(TNBC), the most lethal form of the disease –
as well as a vaccine to prevent ovarian cancer. These vaccine
technologies focus on immunizing against "retired" proteins that
have been found to be expressed in certain forms of cancer. Anixa's
unique business model of partnering with world-renowned research
institutions on clinical development allows the Company to
continually examine emerging technologies in complementary fields
for further development and commercialization. To learn more, visit
www.anixa.com or follow Anixa on Twitter, LinkedIn,
Facebook and YouTube.
Forward-Looking Statements: Statements that are
not historical fact may be considered forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements are not statements of
historical facts, but rather reflect Anixa's current expectations
concerning future events and results. We generally use the words
"believes," "expects," "intends," "plans," "anticipates," "likely,"
"will" and similar expressions to identify forward-looking
statements. Such forward-looking statements, including those
concerning our expectations, involve risks, uncertainties and other
factors, some of which are beyond our control, which may cause our
actual results, performance or achievements, or industry results,
to be materially different from any future results, performance, or
achievements expressed or implied by such forward-looking
statements. These risks, uncertainties and factors include, but are
not limited to, those factors set forth in "Item 1A - Risk Factors"
and other sections of our most recent Annual Report on Form 10-K as
well as in our Quarterly Reports on Form 10-Q and Current Reports
on Form 8-K. We undertake no obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by law.
You are cautioned not to unduly rely on such forward- looking
statements when evaluating the information presented in this press
release.
Contact:
Mike
Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download
multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-announces-presentation-at-24th-annual-world-vaccine-congress-302084608.html
SOURCE Anixa Biosciences, Inc.